Foley attorneys filed an amicus brief in the United States District Court for the Southern District of New York related to ACLU v. Myriad regarding subject matter patentability of gene patents specifically on isolated DNA. The authors conclude that the U.S. Congress, U.S. courts and the USPTO, as well as the scientific community and biotechnology industry have long relied upon an understanding that claims directed to “isolated DNA” recite patentable subject matter under 35 U.S.C. §101 and the Constitution. The authors maintain that to hold otherwise would have a dramatic negative effect on biotech research as we know it, and will influence the entire business of biotechnology in ways unforeseen or addressed by the plaintiffs in ACLU v. Myriad”
People
Related News
01 May 2024
Press Releases
Foley Continues to Grow Its East Coast Transactions Practice, Adds M&A Partner Jeff Symons in New York
Foley & Lardner LLP announced today that it has strengthened its Transactions Practice with the addition of M&A partner Jeff Symons in New York.
30 April 2024
Press Releases
Foley Ventures Announces Fifth Fund to Invest in Firm Clients
Foley Ventures is pleased to announce Foley Ventures V, its latest venture fund launched in April 2024 to invest in companies and debt and equity fund clients.
24 April 2024
Press Releases
Nathaniel Lacktman Joins Tampa Bay Wave’s HealthTech|X Accelerator Advisory Council
Foley & Lardner LLP partner Nathaniel “Nate” Lacktman will serve as a member of the Advisory Council for Tampa Bay Wave’s inaugural HealthTech|X Accelerator program, an innovative initiative to support high-potential health technology startups ready to scale in Tampa and beyond.